A phase II study of docetaxel in patients with relapsed and refractory Ewing's Tumours

Author： Meyer T.   Mctiernan A.   Whelan J.  

Publisher： Informa Healthcare

ISSN： 1369-1643

Source： Sarcoma, Vol.7, Iss.1, 2003-01, pp. : 13-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer

By Hirose Takashi   Shirai Takao   Ishida Hiroo   Ando Kohichi   Sugiyama Tomohide   Kusumoto Sojiro   Hosaka Takamichi   Nakashima Masanao   Ohmori Tohru   Adachi Mitsuru  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 2, 2007-07 ,pp. : 267-274

Springer Publishing Company

Access to resources Recommend Favorite

Excess Toxicity Associated with Docetaxel and Irinotecan in Patients with Metastatic, Gemcitabine-Refractory Pancreatic Cancer: Results of a Phase II Study

By Ko Andrew   Dito Elizabeth   Schillinger Brian   Venook Alan   Bergsland Emily   Tempero Margaret  

Cancer Investigation, Vol. 26, Iss. 1, 2007-12 ,pp. : 47-52

Informa Healthcare

Access to resources Recommend Favorite

Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation

By Yoshioka Takashi   Sakayori Masato   Kato Shunsuke   Chiba Natsuko   Miyazaki Shukichi   Nemoto Kenji   Shibata Hiroyuki   Shimodaira Hideki   Ohtsuka Kazunori   Kakudo Yuichi   Sakata Yuh   Ishioka Chikashi  

International Journal of Clinical Oncology, Vol. 11, Iss. 6, 2006-12 ,pp. : 454-460

Springer Publishing Company

Access to resources Recommend Favorite

Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours

By Louwerens M.   Smorenburg C.   Sparreboom A.   Loos W.J.   Verweij J.   de Wit R.  

European Journal of Cancer, Vol. 38, Iss. 4, 2002-03 ,pp. : 497-504

Elsevier

Access to resources Recommend Favorite

Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial

By Mathisen Michael S   Ravandi Farhad  

Future Oncology, Vol. 8, Iss. 4, 2012-04 ,pp. : 351-357

Future Medicine

Access to resources Recommend Favorite